Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010–2019

This study found significant reporting rates for TEs in patients treated with JAKinibs across brands and indications, providing additional evidence that JAKinibs may be contraindicated in patients at risk of TEs.